Acadia Pharmaceuticals ACAD Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1.
The official record: Acadia Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Acadia Pharmaceuticals's noncash or part noncash acquisition fixed assets acquired1.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Acadia Pharmaceuticals's noncash or part noncash acquisition fixed assets acquired1?
- Acadia Pharmaceuticals (ACAD) reported noncash or part noncash acquisition fixed assets acquired1 of $0 in Q4 2025.
- How has Acadia Pharmaceuticals's noncash or part noncash acquisition fixed assets acquired1 changed year-over-year?
- Acadia Pharmaceuticals's noncash or part noncash acquisition fixed assets acquired1 decreased by 100.0% year-over-year, from $48.84M to $0.
- What does noncash or part noncash acquisition fixed assets acquired1 mean?
- This represents the value of property, plant, and equipment acquired through non-cash transactions, such as debt financing or exchange of assets. Because these acquisitions do not involve immediate cash outflows, they are disclosed separately from capital expenditures. This metric is essential for assessing the company's true investment in infrastructure beyond what is captured in the cash flow statement.